Drug Profile
Calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma
Alternative Names: Calcifediol extended release - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma; CTAP-101; CTAP101 Capsules; JTT-762; Modified-release calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma; RAYALDEE; Rayaldee; RayaldyLatest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator Cytochroma
- Developer OPKO Health; OPKO Renal; Vifor Fresenius Medical Care Renal Pharma
- Class Antivirals; Calcium regulators; Osteoporosis therapies; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Secondary hyperparathyroidism
- Phase II COVID 2019 infections; Cystic fibrosis
- No development reported Bone disorders
Most Recent Events
- 11 Dec 2023 Phase-II clinical trials in Cystic fibrosis in USA (unspecified route) (OPKO Renal pipeline, December 2023)
- 24 Feb 2023 Phase-III clinical trials in Secondary hyperparathyroidism (In adolescents, In children) in USA (PO) (NCT05543928)
- 16 Sep 2022 OPKO Health plans a phase III trial for Secondary hyperparathyroidism (In children, in adolescents) (PO, Capsule) in October 2022 (NCT05543928)